Hepatocellular Carcinoma
Conditions
Interventions
Experimental group:Interventional therapy combined with target immunotherapy
Sponsors
Dongying People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients who meet the clinical diagnostic criteria of the 2022 Guidelines for the Diagnosis and Treatment of Primary Liver Cancer or are pathologically diagnosed with primary liver cancer, have at least one measurable tumor lesion, and are not suitable for/refuse to undergo surgical resection; 2. Gender unlimited, 18-75 years old; 3. CNLC Ib-IIIb; 4. Child-Pugh A-B ; 5. ECOG 0-1; 6. No serious complications; 7. The patient's expected survival was more than 3 months; 8. Agree to participate in the study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Huge liver tumor (=60% liver volume); 2. Patients with diffuse liver cancer; 3. unstable systemic disease or uncontrolled infection; 4. Dysfunction of renal function and coagulation that is difficult to correct; 5. Bleeding from esophageal or fundus varices caused by portal hypertension in the past 6 months, or any life-threatening bleeding event within 3 months; 6. Any unstable condition or condition that may compromise the patient's safety and his/her compliance with the study; 7. Any adverse events that require termination of treatment; 8. The patient or legal representative requests that treatment be discontinued; 9. Unable to complete the treatment plan for various reasons, or the patient lost follow-up; 10. The investigator considered other patients not suitable to participate in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Objective response rate;Disease control rate; | — |
Countries
China
Contacts
Public ContactBo Yuan
Dongying People's Hospital
Outcome results
None listed